Kalana S. Athukorala

Kalana S. Athukorala

Auto-generated profile, based on publicly available information

Kalana S. Athukorala

Department of Biomedical Engineering, University of Michigan-Ann Arbor

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
JRJeffrey Ruth
Jeffrey Ruth
MGMikel Gurrea-Rubio
Mikel Gurrea-Rubio
KAKalana S. Athukorala
Kalana S. Athukorala
SRStephanie M. Rasmussen
Stephanie M. Rasmussen
DWDaniel P. Weber
Daniel P. Weber
DFDavid Fox
David Fox
Limitations of checkpoint inhibitor cancer immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Since CD318, a novel CD6 ligand, is associated with the aggressiveness and metastatic potential of human cancers, we tested the effect of an anti-CD6 monoclonal antibody, UMCD6, on killing of cancer cells by human lymphocytes. UMCD6 augmented killing of breast, lung, and prostate cancer cells through direct effects on both CD8 + T cells and NK cells, increasing cancer cell death and lowering cancer cell survival in vitro more robustly than monoclonal antibody checkpoint inhibitors that interrupt the programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) axis. UMCD6 also augmented in vivo killing by human peripheral blood lymphocytes of a human breast cancer line xenotransplanted into immunodeficient mice. Mechanistically, UMCD6 upregulated the expression of the activating receptor NKG2D and downregulated expression of the inhibitory receptor NKG2A on both NK cells and CD8 + T cells, with concurrent increases in perforin and granzyme B production. The combined capability of an anti-CD6 monoclonal antibody to control autoimmunity through effects on CD4 + lymphocyte differentiation while enhancing killing of cancer cells through distinct effects on CD8 + and NK cells opens a potential new approach to cancer immunotherapy that would suppress rather than instigate autoimmunity.

13 April 2020 in Journal of Biological Methods
Verified
Journal Article
Open access
PDF file
TLThomas M. Lanigan
Thomas M. Lanigan
SRStephanie M. Rasmussen
Stephanie M. Rasmussen
DWDaniel P. Weber
Daniel P. Weber
KAKalana S. Athukorala
Kalana S. Athukorala
PCPhillip L. Campbell
Phillip L. Campbell
JRJeffrey Ruth
Jeffrey Ruth
Cancer immunotherapy is a rapidly advancing and viable approach to treating cancer along with more traditional forms of therapy. Real-time cell analysis technologies that examine the dynamic interactions between cancer cells and the cells of the immune system are becoming more important for assessment of novel therapeutics. In this report, we use the IncuCyte® imaging system to study the killing potential of various immune cells on cancer cell lines. The IncuCyte® system tracks living cells, labeled by a red fluorescent protein, and cell death, as indicated by the caspase-3/7 reagent, which generates a green fluorescent signal upon activation of apoptotic pathways. Despite the power of this approach, obtaining commercially fluorescent cancer cell lines is expensive and limited in the range of cell lines that are available. To overcome this barrier, we developed an inexpensive method using a lentiviral construct expressing nuclear localized mKate2 red fluorescent protein to stably label cancer cells. We demonstrate that this method is effective in labeling a wide variety of cell lines, allowing for analyses of different cancers as well as different cell lines of the same type of cancer.

7 May 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
NBNathalie Burg
Nathalie Burg
RMRyan Malpass
Ryan Malpass
LALinda Alex
Linda Alex
MTMiles Tran
Miles Tran
EEEric Englebrecht
Eric Englebrecht
JSJane E Salmon
Jane E Salmon
In rheumatoid arthritis, inflammatory mediators extravasate from blood into joints via gaps between endothelial cells (ECs), but the contribution of ECs is not known. Sphingosine 1-phosphate receptor 1 (S1PR1), widely expressed on ECs, maintains the vascular barrier. Here, we assessed the contribution of vascular integrity and EC S1PR1 signaling to joint damage in mice exposed to serum-induced arthritis (SIA). EC-specific deletion of S1PR1 or pharmacological blockade of S1PR1 promoted vascular leak and amplified SIA, whereas overexpression of EC S1PR1 or treatment with an S1PR1 agonist delayed SIA. Blockade of EC S1PR1 induced membrane metalloproteinase-dependent cleavage of vascular endothelial cadherin (VE-cadherin), a principal adhesion molecule that maintains EC junctional integrity. We identified a disintegrin and a metalloproteinase domain 10 (ADAM10) as the principal VE-cadherin “sheddase.” Mice expressing a stabilized VE-cadherin construct had decreased extravascular VE-cadherin and vascular leakage in response to S1PR1 blockade, and they were protected from SIA. Importantly, patients with active rheumatoid arthritis had decreased circulating S1P and microvascular expression of S1PR1, suggesting a dysregulated S1P/S1PR1 axis favoring vascular permeability and vulnerability. We present a model in which EC S1PR1 signaling maintains homeostatic vascular barrier function by limiting VE-cadherin shedding mediated by ADAM10 and suggest this signaling axis as a therapeutic target in inflammatory arthritis.

4 June 2026 in Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
KGKate V. Griffin
Kate V. Griffin
SHSarah E. Hocevar
Sarah E. Hocevar
SSSamantha R. Schwartz
Samantha R. Schwartz
BSBrooke M. Smiley
Brooke M. Smiley
BRBrian C. Ross
Brian C. Ross
LSLonnie D Shea
Lonnie D Shea
Trauma to the spinal cord initiates an inflammatory response causing secondary damage, which collectively can result in loss of function below the level of the injury. The unbalanced risk–benefit ratio of methylprednisolone led to development of therapeutic nanoparticles (NPs) that associate with circulating monocytes and neutrophils to reduce inflammation and secondary damage and improve functional recovery in a female mouse model of cervical hemisection spinal cord injury. Herein, we investigate the mechanisms occurring during the acute phase of injury by which NPs directly and indirectly modulate the phenotype and trafficking of monocytes and neutrophils and computationally catalog the communication network among cell types within the injury microenvironment. Using adoptive transfer to monitor trafficking, NP treatment reduced the extent of myeloid cell recruitment to the injury yet did not impact the composition of adoptively transferred monocytes or neutrophils. The proportion of inflammatory monocytes was reduced with NP treatment, and single-cell sequencing analysis indicated increased polarization toward pro-regenerative phenotypes. Sequencing analysis also demonstrated that outgoing signals from monocytes and neutrophils influenced the phenotype of numerous cell types, including endothelial cells, fibroblasts, oligodendrocyte progenitor cells, and Schwann cells. Signaling between cell compartments involves a combination of soluble and matrix signals, with NP treatment enhancing expression of genes associated with anti-inflammatory phenotypes, angiogenesis, neuroprotection, and promotion of axon outgrowth or decreasing expression of inhibitors to regeneration. Collectively, NP delivery leads to direct and indirect effects on monocytes and neutrophils, which subsequently influence gene expression and intercellular signaling networks that promote a pro-regenerative environment.